Inactive Instrument

Highlights Five Prime Therapeutics, Inc.

Equities

FPRX

US33830X1046

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Amgen's 2Q Profit Drops on Acquisition Write-off, Revenue Growth Beats Wall Street Target	21-08-03	DJ
Amgen Inc. completed the acquisition of Five Prime Therapeutics, Inc..	21-04-15	CI
FDA Approves Five Prime’s Request for Breakthrough Therapy Designation	21-04-15	CI
Amgen : Seen Logging 25% Revenue Compound Annual Growth in Asia Pacific Over 10 years, Oppenheimer Says	21-03-30	MT
Five Prime Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-22	CI
Amgen : Five Prime Takeover is Incremental Positive Deal, Should Help Amgen Grow Business in Asia, Says Mizuho	21-03-04	MT
Five Prime Therapeutics : Shares Gain After Amgen Deal	21-03-04	DJ
Amgen : to Acquire Five Prime Therapeutics for $1.9 Billion to Strengthen Oncology Portfolio, Support Global Expansion	21-03-04	MT
Amgen : to Acquire Five Prime Therapeutics for $1.9 Billion	21-03-04	MT
Amgen Inc. entered into an agreement to acquire Five Prime Therapeutics, Inc. for $1.8 billion.	21-03-03	CI
Five Prime Therapeutics : Says Trial of Gastric Cancer Treatment Candidate Met Objectives	21-01-15	MT
Five Prime Therapeutics, Inc. Announces Clinical Results from Global, Randomized, Double-Blind Placebo-Controlled Phase 2 Fight Trial Evaluating First-In-Class Targeted Therapy Bemarituzumab in Advanced Gastric or Gastroesophageal Junction Cancer	21-01-15	CI
Five Prime Therapeutics, Inc. to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology Gastrointestinal (GI) Cancers Virtual Annual Symposium	20-12-09	CI
Five Prime Therapeutics : Climbs to Late 2017 Level on Drug Candidates Prospects; Plans Share Offer	20-11-12	MT
Five Prime Therapeutics, Inc. Presents First Preclinical Data on Anti-CCR8 Antibody FPA157	20-11-11	CI
Five Prime Therapeutics, Inc. Announces Positive Topline Results from the Global, Randomized, Double-Blind Placebo-Controlled Phase 2 Fight Trial	20-11-10	CI
Five Prime Therapeutics : Q3 Misses Street Estimates -- Stock Down 3.5% After-Hours	20-11-03	MT
Five Prime Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-03	CI
Five Prime Therapeutics : Earnings Flash (FPRX) FIVE PRIME THERAPEUTICS Posts Q3 Revenue $2M, vs. Street Est of $4.55M	20-11-03	MT
Five Prime Therapeutics, Inc. to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting	20-11-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Five Prime Therapeutics, Inc.

Equities

FPRX

US33830X1046

Highlights

Filters